Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab

Phase 3

Completed

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: Chemotherapy (Induction Period)
Drug: Rituximab

First Posted Date: 2011-10-28

Last Posted Date: 2019-08-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 692

Registration Number: NCT01461928

Locations: 🇧🇬
Tokuda Hospital Sofia; Hematology department, Sofia, Bulgaria
🇦🇹
Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Hämatologie & Hämostaseologie, Wien, Austria
🇨🇴
Instituto Nacional de Cancerologia; Hematology, Bogota, Colombia

and more 177 locations

An Observational Study of Avastin (Bevacizumab) in Patients With HER2-metastatic or Locally Advanced Breast Cancer

Completed

Conditions: Breast Cancer

First Posted Date: 2011-10-27

Last Posted Date: 2016-01-26

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 228

Registration Number: NCT01461044

A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer

Phase 2

Completed

Conditions: Gastric Cancer

Interventions: Drug: Capecitabine
Drug: Cisplatin
Drug: Pertuzumab
Drug: Trastuzumab

First Posted Date: 2011-10-27

Last Posted Date: 2018-08-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 30

Registration Number: NCT01461057

Locations: 🇨🇿
Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia
🇧🇪
UZ Leuven Gasthuisberg, Leuven, Belgium
🇮🇹
Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2, Milano, Lombardia, Italy

and more 21 locations

ACCU-CHEK® Aviva Expert Study: Does Use of a Bolus Advisor Improve Glycemic Control in Patients Not Achieving Optimal Control Using Multiple Daily Injections (MDI)?

Not Applicable

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 1

Interventions: Device: Aviva Expert blood glucose meter
Device: Aviva Nano blood glucose meter

First Posted Date: 2011-10-26

Last Posted Date: 2014-02-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 218

Registration Number: NCT01460446

ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment

Phase 2

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Placebo
Drug: RO4995819

First Posted Date: 2011-10-24

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 357

Registration Number: NCT01457677

A Study of RO4995819 in Healthy Elderly Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: RO4995819
Drug: Placebo

First Posted Date: 2011-10-24

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 30

Registration Number: NCT01457664

A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)

Phase 1

Completed

Conditions: Juvenile Idiopathic Arthritis

Interventions: Drug: Tocilizumab

First Posted Date: 2011-10-20

Last Posted Date: 2019-11-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 11

Registration Number: NCT01455701

Locations: 🇺🇸
Hackensack University Medical Center; Pediatric Rheumatology, Hackensack, New Jersey, United States
🇺🇸
Children's National Medical Center; Pediatric Rheumatology, Washington, District of Columbia, United States
🇺🇸
The Floating Hospital for Children at Tufts Medical Center, Boston, Massachusetts, United States

and more 17 locations

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Phase 3

Terminated

Conditions: Gastric Cancer

Interventions: Drug: Capecitabine
Drug: Cisplatin
Drug: Herceptin

First Posted Date: 2011-10-12

Last Posted Date: 2016-11-28

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 296

Registration Number: NCT01450696

A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)

Phase 4

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: peginterferon alfa-2a
Drug: ribavirin [Copegus]

First Posted Date: 2011-10-06

Last Posted Date: 2016-07-25

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 129

Registration Number: NCT01447420

An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: Peg-IFN Alfa-2b
Drug: Peg-IFN Alfa-2a
Drug: Ribavirin
Drug: Boceprevir
Drug: Telaprevir

First Posted Date: 2011-10-06

Last Posted Date: 2017-03-30

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 4442

Registration Number: NCT01447446

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy